| Temporal dynamics of Wnt-dependent transcriptome reveal an oncogenic Wnt/MYC/ribosome axis. | None |
| The first exon of the c-myc proto-oncogene contains a novel positive control element. | None |
| MYC oncogene involved in a t(8;22) chromosome translocation is not altered in its putative regulatory regions. | None |
| Expression of the c-myc oncogene under control of an immunoglobulin enhancer in E mu-myc transgenic mice. | None |
| N-myc proto-oncogene expression during organogenesis in the developing mouse as revealed by in situ hybridization. | None |
| IKBKE/TBK1-sensitive AML cells typically possess an MYC oncogenic signature. Consistent with this finding, the MYC oncoprotein was significantly downregulated upon IKBKE/TBK1 inhibition. | None |
| Proto-oncogene expression and nuclear factor specifically bound to c-myc gene in peripheral blood mononuclear cells from progressive systemic sclerosis patients as the indicator of clinical activity. | None |
| Autoantibody to human c-myc oncogene product in autoimmune patients sera. | None |
| Expression of the c-myc oncoprotein in human metaplastic epithelial cells of fibrocystic disease. | None |
| Potential multiple functions of the v-myc oncogene within a single cell clone of OK10 retrovirus-transformed quail fibroblasts. | None |
| Elevated expression of c-myc proto-oncogene in scleroderma fibroblasts. | None |
| Possible involvement of protein kinase C and calcium ion in growth factor-induced expression of c-myc oncogene in Swiss 3T3 fibroblasts. | None |
| Immunoglobulin genes and the c-myc oncogene in plasmacytomagenesis. | None |
| How reliable is amino acid sequence homology in predicting similarity of structure and function of c-myc and Ad12 E1A oncogenic proteins?. | None |
| The c-myc oncogene perturbs B lymphocyte development in E-mu-myc transgenic mice. | None |
| Ibtk sustains the oncogenic activity of Myc by inhibiting apoptosis of murine pre-cancerous B cells, as a cell-specific mechanism. | None |
| PHF10 expression in cells of different lines is activated by the c-MYC oncogene. Since PHF10 stimulates cell proliferation, its c-MYC-dependent activation in cancer cells should lead to an increase in their proliferation rate. | None |
| The processed SNHG15 is overexpressed in CRC tumors and its expression is highly correlated with poor survival of patients. Interestingly, SNHG15 is more highly expressed in tumors with high levels of MYC expression, while MYC protein binds to two E-box motifs on SNHG15 sequence, indicating that SNHG15 transcription is directly regulated by the oncogene MYC. | None |
| ARIEL recruits mediator proteins to the ARID5B enhancer, promotes enhancer-promoter interactions, and activates the expression of ARID5B, thereby positively regulating the TAL1-induced transcriptional program and the MYC oncogene. | None |
| Two oncogenic Myc proteins, c-Myc and N-Myc, transcriptionally control the expression of the mitochondrial chaperone TNFR-associated protein-1 (TRAP1) in cancer. This Myc-mediated regulation preserved the folding and function of mitochondrial oxidative phosphorylation (OXPHOS) complex II and IV subunits, dampened reactive oxygen species production, and enabled oxidative bioenergetics in tumor cells. | None |